Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. reported a 9.8% revenue increase to RMB2,746.1 million in the first half of 2024, mainly driven by robust drug sales and expanding R&D services. The company also saw a significant profit rise to RMB386.3 million, attributed to the successful commercialization of core products and growing sales. Key developments include various global approvals for their drugs, including HANQUYOU,…
Read More…